Skip to main content
Clinical Trials/NCT01128478
NCT01128478CompletedPhase 2

Early Enteral Tube Feeding Compared With Pancreas Rest in Patients With Acute Pancreatitis: a Randomized Controlled Trial

University of Auckland, New Zealand1 site in 1 country35 target enrollmentStarted: May 1, 2010Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
35
Locations
1
Primary Endpoint
Length of hospital stay

Study Overview

Brief Summary

Pain relapse during oral refeeding occurs in at least one-fifth of patients with acute pancreatitis. The study hypothesis is that early administered enteral tube feeding might reduce a risk of pain relapse and shorten the length of hospital stay in patients with acute pancreatitis.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • diagnosis of acute pancreatitis
  • age 18 years or older
  • written informed consent

Exclusion Criteria

  • > 96 hours after onset of symptoms
  • > 24 hours after hospital admission
  • organ failure by the time of randomization
  • infectious complications before randomization
  • received artificial nutrition before randomization
  • previously enrolled into the trial
  • chronic pancreatitis
  • post-ERCP pancreatitis
  • intraoperative diagnosis of acute pancreatitis
  • pregnancy
  • malignancy

Outcomes

Primary Outcomes

Length of hospital stay

Time Frame: Up to 3 months

Secondary Outcomes

  • Mortality(Up to 6 months)
  • Hospital readmission(Up to 6 months)
  • Quality of life(Up to 6 months)
  • Pain relapse(Up to 3 months)
  • Local and systemic complications(Up to 3 months)
  • Feeding intolerance(Up to 3 months)
  • Time to solid oral food tolerated(Approx. one week)
  • Pain-free time(Up to 3 months)

Investigators

Sponsor
University of Auckland, New Zealand
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Max Petrov

Principal Investigator

University of Auckland, New Zealand

Study Sites (1)

Loading locations...

Similar Trials